GlassScriptPhysician profile
Stanley P Weiselberg
NPI 1033191648
$1,358.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $118 · 2021: $527.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $476.90 | 2019-2021 | |
| Abbvie INC. | $442.35 | 2019-2021 | |
| Janssen Biotech, INC. | $173.88 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.30 | 2021 | |
| Ucb, INC. | $48.18 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $33.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.67 | 2019 | |
| Gilead Sciences, INC. | $30.00 | 2019 | |
| Medtronic, INC. | $17.90 | 2021 | |
| Qol Medical, LLC | $13.79 | 2019 | |
| Conmed Corporation | $13.28 | 2021 | |
| Hospira, INC. | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Weiselberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.